Adalimumab biosimilar(BioXpress)

阿达木单抗生物类似药（BioXpress）

Report date: 2022/03/16 14:51:47

Base Information

Drug NameAdalimumab biosimilar(BioXpress)
Drug Alias NameBX-2922BXT-2922
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsUveitisCrohn DiseaseColitis, Ulcerative +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBioxpress Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesBioxpress Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsUveitisCrohn DiseaseColitis, Ulcerative +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A